This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy

Introducing NephJC’s brand new editorial internship class of 2026-2027

In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.

Black Americans have an increased risk of chronic kidney disease (CKD) compared with individuals without African ancestry. Variants designated G1 and G2 in the apolipoprotein L1 protein encoded by the APOL1 gene are a major contributor to this increased risk.1 These variants arose independently, rar...

HTRA1 is a common autoantigen in PLA2R-negative MN among very elderly patients, occurring in approximately one in five cases aged 80 years or more. These findings support inclusion of HTRA1 testing in diagnostic evaluation of antigen-negative MN in patients 80 years and older and suggest the existen …

The complement system plays a central role in glomerular disease development and resolution. Currently, renal biopsies assess the presence of complement through limited immunofluorescence stains (C3 and C1q). With more than 50 total proteins and fragments involved in the complement cascade, this met …

The NephJC Kidneys are back for the eighth year! Nominate you favorites of 2025- 2026!

2025 was rich in successful stories. Here are the top 10 that impressed our audience.

YouTube video by Arkana Laboratories

Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.

This week, we will discuss the clinical significance of eGFRdiff, the difference in eGFRcys (cystatin C) and eGFRcr (creatinine).

Immune checkpoint inhibitor-associated acute interstitial nephritis presents significant clinical challenges. There are no reliable non-invasive biomarkers and kidney biopsy remains the gold standard ...

This week, we will discuss a registry trial: can a nationwide nudge fix a CKD treatment gap?

This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.